Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
clinical trials
life sciences
national blog main
new york
2
×
new york blog main
new york top stories
alirocumab
allergan
alnylam pharmaceuticals
amgen
biotech
boston top stories
bristol-myers squibb
clinical data
drugs
evercore isi
evolocumab
genfit
gilead sciences
heart attack
inclisiran
intercept pharmaceuticals
joseph swartz
ldl-c
liver
liver disease
madrigal pharmaceuticals
mark pruzanski
medicines co.
nash
national top stories
nonalcoholic steatohepatitis
obeticholic acid
pcsk9 inhibitors
regeneron pharmaceuticals
rna interference
san diego blog main
san diego top stories
san francisco blog main
What
data
2
×
drug
2
×
new
alnylam
approved
based
cholesterol
disease
evidence
fatty
heart
horizon
intercept
known
lasting
liver
long
looms
lowering
marketed
medco
medicine
medicines
nash
nonalcoholic
partner
pharmaceuticals
presented
reckoning
rna
steatohepatitis
supporting
term
touts
track
use
Language
Current search:
drug
×
data
×
" new york "
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug